bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · IEX Real-Time Price · USD
2.170
-0.050 (-2.25%)
At close: Jul 2, 2024, 4:00 PM
2.270
+0.100 (4.61%)
After-hours: Jul 2, 2024, 7:55 PM EDT
Company Description
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung.
It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
bioAffinity Technologies, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Sep 1, 2022 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Ms. Maria Zannes J.D. |
Contact Details
Address: 22211 West Interstate-10, Suite 1206 San Antonio, Texas 78257 United States | |
| Phone | 210-698-5334 |
| Website | bioaffinitytech.com |
Stock Details
| Ticker Symbol | BIAF |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.13 |
| CIK Code | 0001712762 |
| CUSIP Number | 09076W109 |
| ISIN Number | US09076W1099 |
| Employer ID | 46-5211056 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Maria Zannes J.D. | Founder, President, Chief Executive Officer and Director |
| Steven Girgenti | Founder and Executive Chairman of the Board |
| Michael Dougherty C.P.A., M.B.A. | Vice President and Chief Financial Officer |
| Xavier T. Reveles M.S. | Chief Operating Officer |
| Dr. Vivienne I. Rebel M.D., Ph.D. | Executive Vice President and Chief Medical and Science Officer |
| Timothy P. Zannes J.D. | Executive Vice President, Secretary and General Counsel |
| Julie Anne Overton | Director of Communications |
| Dallas J. Coleman | National Director of Sales |
| Dr. William Bauta Ph.D. | Senior Vice President of Therapeutics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 5, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 5, 2024 | 8-K | Current Report |
| May 22, 2024 | 424B3 | Prospectus |
| May 22, 2024 | 424B3 | Prospectus |
| May 16, 2024 | 8-K | Current Report |
| May 15, 2024 | 10-Q | Quarterly Report |
| Apr 17, 2024 | 424B3 | Prospectus |
| Apr 15, 2024 | EFFECT | Notice of Effectiveness |
| Apr 15, 2024 | ARS | Filing |
| Apr 15, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |